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Abstract
Background: The mimotopes of viruses are considered as the good targets for vaccine design. We prepared
mimotopes against multiple subtypes of influenza A and evaluate their immune responses in flu virus challenged
Balb/c mice.
Methods: The mimotopes of influenza A including pandemic H1N1, H3N2, H2N2 and H1N1 swine-origin influenza
virus were screened by peptide phage display libraries, respectively. These mimotopes were engineered in one
protein as multi- epitopes in Escherichia coli (E. coli) and purified. Balb/c mice were immunized using the multi-
mimotopes protein and specific antibody responses were analyzed using hemagglutination inhibition (HI) assay
and enzyme-linked immunosorbent assay (ELISA). The lung inflammation level was evaluated by hematoxylin and
eosin (HE).
Results: Linear heptopeptide and dodecapeptide mimotopes were obtained for these influenza virus. The
recombinant multi-mimotopes protein was a 73 kDa fusion protein. Comparing immunized infected groups with
unimmunized infected subsets, significant differences were observed in the body weight loss and survival rate. The
antiserum contained higher HI Ab titer against H1N1 virus and the lung inflammation level were significantly
decreased in immunized infected groups.
Conclusions: Phage-displayed mimotopes against multiple subtypes of influenza A were accessible to the mouse
immune system and triggered a humoral response to above virus.
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Background
Influenza A can cause significant morbidity and mortality
levels in human. The human influenza A pandemics
killed about millions of people worldwide over the past
(1918 H1N1 Spanish, 1957 H2H2 Asian, 1968 H3N2
Hong Kong, and 2009 H1N1 Mexico) and seasonal influ-
enza A killed more than 250,000 each year [1-3]. The
pathogenic viruses are classified by their surface proteins:
hemagglutinin and neuraminidase [4,5]. There are 16
hemagglutinin subtypes (H1-16) and 9 neuraminidase
subtypes (N1-9) on the influenza viral surface [6].
Although Neuraminidase inhibitors and amantadine have
been used to treat influenza patients, they have limited
efficacy and their widespread use is likely to result in
resistant viruses [7,8]. Consequently, vaccination remains
t h em o s te f f e c t i v es t r a t e g yt op r e v e n ti n f l u e n z av i r u s
attack [9,10]. Developing a new vaccine which induces a
b r o a di m m u n er e s p o n s ea g a inst multiple subtypes of
influenza A is a urgent strategy for the disease control.
The viruses mimotopes are considered to be good tar-
gets for the vaccine design since they can induce antibo-
dies against both viral original and mutant antigen [11].
Protective immune responses by mimotope immuniza-
tion have been verified in many infectious diseases
[11-14]. The phage display libraries have been used for
novel therapeutic and diagnostic drugs development in
our and others previous studies [15-18]. Random
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ing sequences that mimic conformational epitopes
(mimotopes) either structurally or immunologically [11].
The aim of this study was to prepare mimotopes against
multiple subtypes of influenza A and evaluate its
immune responses in Balb/c mice with flu virus
challenge.
Methods
Antibodies
C179 monoclonal antibody (A/H2N2 subtype) was pur-
chased from Takara Bio Inc (Otsu, Shiga, Japan); Mouse
monoclonal antibody (IV.C102) against influenza virus
A strain H1N1 was from Santa Cruz (Santa Cruz, CA,
USA); Purified H3N2 goat polyclonal IgG specific to
influenza A/Texas 1/77 was from Virostat (Portland,
ME, USA); SIV sera were prepared from patients hospi-
talized by swine-origin influenza virus A/2009 and their
binding activities were tested by ELISA. Endotoxin was
removed by purification with polymyxin B chromatogra-
phy. Endotoxin levels were < 0.1 unit/μgo fp r o t e i nb y
the Limulus Amebocyte Lysate QCL-1000 pyrogen test
(Cambrex).
Phage display libraries
Ph.D.-7, Ph.D.-12 and Ph.D.-C7C were produced by
New England Biolabs, Inc (Ipswich, MA, USA), with
random linear 7-mer, 12-mer or cyclic 7-mer peptides
fused to minor coat proteins (pIII) of M13 filamentous
phages.
Screening of phage libraries for H2N2 antibody-reactive
phages
C179 (0.2 ml, 10 μg/ml) was coated on three wells of
24-wells microplate at 4°C overnight. The coated wells
were blocked with 2% bovine serum albumin (BSA) at
37°C for 1 h, then washed with Tris￿HCl buffer solution
(TBS) containing 0.1% Tween-20 (TBST) for 6 times.
Ten microliter Ph.D.-7 (2 × 10
11 pfu), Ph.D.-12 (1.5 ×
10
11 pfu) and Ph.D.-C7C (2 × 10
11 pfu) libraries diluted
with 0.2 ml TBST were dropped into the coated wells
respectively. The incubation wells were rocked gently
for 30 min, followed by discarding nonbinding phages.
The binding phages were eluted with 0.2 M Glycine-
HCl (pH 2.2), 1 mg/ml BSA and neutralized with 1 M
Tris￿HCl (pH 9.1). The eluted phages were used to
infect log-phase bacteria ER2738, concentrated by PEG
precipitation and submitted to the second round of
selection. The following selections were performed as
above except that the Tween-20 concentration was
raised from 0.1% to 0.5% in the wash steps. After 3
rounds of selection, the eluted phages were used for pla-
que isolation. 32 plaque clones were amplified for ELISA
test and single-strand DNA preparation.
Screening of phage libraries for H1N1 antibody-reactive
phages
IV.C102 (0.2 ml, 10 μg/ml) was coated on three wells of
24-wells microplate at 4°C overnight. The blocking and
bio-spanning procedures were carried as did in C179
antibody, except that the binding phages were eluted
with IV.C102 (0.2 ml, 10 μg/ml). After 3 rounds of
selection, the eluted phages were used for plaque
isolation.
Screening of phage libraries for H3N2 antibody-reactive
phages
H3N2 polyclonal antibody (30 μg/ml) and goat IgG (100
μg/ml) were coated respectively. After blocking with
BSA and washing with TBST for 6 times, Ph.D.-7, Ph.
D.-12 and Ph.D.-C7C libraries were added into the goat
IgG-coated wells for 30 min incubation. Then, the non-
binding phages were transferred to H3N2 polyclonal
antibody-coated wells for additional 30 min incubation.
After that, the non-binding phages were discarded, and
the binding phages were eluted with H3N2 polyclonal
antibody. The eluted phages were amplified in bacteria
ER2738 and used in the following selections as above.
Screening of phage libraries for swine-origin influenza
antibody-reactive phages
Goat anti-human IgG (100 μg/ml) was coated on six
wells. After blocking, three wells were added with diluted
SIV sera (1:20), the others were added with human IgG
(100 μg/ml). Then they were placed at 4°C overnight and
washed with TBST for 6 times. Peptide phage display
libraries were added into the IgG wells for 30 min incu-
bation. Subsequently, the nonbinding phages solutions
were transferred to the sera wells for 30 min incubation.
Then, the binding phages at the sera wells were eluted
with goat anti-human IgG. The eluted phages were used
for plaque isolation at the end of the 3rd selection.
Binding specificity of the selected phage by ELISA and
DNA sequencing
Ninety-six-well plates were coated with mAb and BSA
(10 μg/ml, 100 μl) by incubation at 4°C overnight, and
blocked with 5% BSA in TBS. Affinity-selected phage
were added to the wells and allowed to bind at 37°C for
1 h. After the unbounded phages were removed with 5%
TBST, the bound phages were detected by incubation
with peroxidase-labelled murine anti-M13 antibodies
(Pharmacia). The bound peroxidase was determined by
incubation with Opheny lenediamine dihydrochloride
(Pierce Chemicals) in buffer (30 mM citrate, 70 mM
Na2HPO4, and 0.02% H2O2, pH 5.5). When the reac-
tion was stopped by the addition of 3 N HCl, A450 nm
was determined with an ELISA reader (BioRad). All the
assays were carried out in triplicate.
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for immune-analysis. The nucleotide sequence of the
gene III insert was determined as the instruction man-
ual. The amino acid sequence of the insert was deduced
f r o mt h en u c l e o t i d es e q u e n c ea n dw a sc o m p a r e dw i t h
native influenza A. The sequences that appeared > 3
times among the selected phage clones were classified as
the consensus sequence. The aligned amino acid
sequences shared by three or more identical amino
acids within the dodecapeptides (heptapeptides) were
determined as the mimotopes of the matched protein
sequences.
Multi-mimotope gene synthesis
The 7- and 12-mer mimotopes of H1N1, H2N2, H3N2
and SIV were linked by GSGGS with the mimotope
sequences of SIV7-SIV12-H1N17-H1N112-H3N27-
H3N212-H2N27-H2N212. Each mimotope represents
the peptide with the highest frequency on phage surface.
The codon usage was optimized by species preference
and GC content. The gene was synthesized with EcoRI /
BamH I enzyme site by Sangon (Shanghai, China).
Multi-mimotope expression
The multi-mimotope gene was cut with EcoRIa n d
BamH I endonucleases, and ligated separately into pre-
cut pGEX-2 T-1, pGEX-4 T-1 and pET43a (+) plas-
mids. The ligation products were used to transform
competent Trans 109 E. coli cells, which were selected
on LB-AMP agar plates at 37°C for 12 h. Three AMP-
resisitant clones were picked randomly for plasmids
extraction, EcoRI / BamH I digestion and gene sequen-
cing. The confirmed plasmids with correct insert were
transformed into competent BL21 (DE3) E. coli cells
for protein expression. Four transformed bacteria BL21
(DE3) clones were picked from LB-AMP agar plates
for culturing overnight in LB-AMP medium. The
resultant bacteria were inoculated into 5 ml fresh med-
ium, cultured to mid-log growth phase for protein
expression induction with 1 mM IPTG. After 12 h
induction, the bacteria sample was aliquot for SDS-
PAGE analysis.
Multi-mimotope purification
One hundred milliliters of BL21 (DE3) E. coli cells con-
taining pET43a (+)-multi-mimotope plasmids were
induced with IPTG for 12 h. The resultant medium was
centrifuged with 8000× g for 10 min and the pellet was
r e s u s p e n d e di n t o1 0m lo f2 0m MT B S( p H7 . 9 ) .T h e
cells were broken by ultrasounding with 100 W for 100
s, followed by centrifuging to remove the cell debris.
The supernatant was filtered through 0.22 μmm e m -
brane and then loaded onto pre-equilibrated Ni
2+-NTA-
resin. Then, the resin was rinsed by TBS containing 5
mM imidazole; the binding protein was eluted by TBS
containing variable imidazole.
In vitro binding
The recombinant multi-mimotope was coated on 96-
well microplate with concentration of 10 μg/ml at 4°C
overnight, followed by blocking with 2% BSA at 37°C
for 2 h. The bait antibodies including C179, H1N1
monoclonal antibody, H3N2 polyclonal antibody and
SIV sera were added into wells separately to incubate
with coated protein at 37°C for 2 h. The wells were
washed with PBST for 6 times. Then, HRP-conjugated
secondary antibodies were added for binding at 37°C for
2 h. The TMB solution was then added into the wells
for color development, which was stopped with 3 N
HCl. The unrelated protein BSA was coated as control
protein to determine the binding specificity of multi-
mimotope to the antibodies.
Animal immunisation
To evaluate the potential of the selected mimotopes as
experimental vaccine candidates, purified phage mimo-
topes were used to immunise female inbred specific-
p a t h o g e n - f r e eB A L B / cm i c et h r o u g hi n t r a p e r i t o n e a l
administration.
The multi-mimotope protein was concentrated to 1
mg/ml and injected intraperitoneally (50 μg, 100 μg, 200
μg per mouse) or subcutaneously (100 μgp e rm o u s e )
into BALB/c mice (9 per group) as emulsion (1:1) with
complete Freund’s adjuvant (CFA) for the first immuni-
zation and with incomplete Freund’sa d j u v a n t( I F A )f o r
the booster injection at 14 days later. The control group
were injected with PBS. Ten days after the booster injec-
tion, except for control group, other 5 groups were chal-
lenged with 2 × 10
3 f.f.u A/Puerto Rico/8/1934 (H1N1)
by intranasal inoculation of 50 μl per mouse. Mice were
weighed on the day of virus challenge and then every
three days for two weeks. Two weeks after the challenge,
lungs were removed for pathological examination. Blood
samples were taken to measure serum Ab titers by
ELISA. Animals were conducted and approved by the
Institutional Animal Care and Use Committee of the
Academy of Military Medical Science, under protocol
number 0054921. All experiments were performed
according to institutional guidelines.
Serum Ab assay by ELISA
The concentrations of IgG Abs against H1N1 influenza
virus were measured by ELISA. Purified antigen was
coated on the microtitre plates (100 μl/well, 5 μg/ml in
coating solution, 0.1 M sodium bicarbonate, pH 9.6)
(Corning, Corning, NY, USA) and incubated at 4°C
overnight. Serial 2-fold dilutions of sera (100 μl/well)
from each group of unimmunized or immunized and
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Goat anti-mouse IgG HRP (1:10,000 dilution with wash-
ing buffer) was used to detect IgG Abs and O-phenyle-
nediamine dihydrochloride (Pierce Chemicals) was used
as substrate for HRP and the reaction was monitored at
an absorption of 492 nm using an ELISA reader (Lab-
systems Multiskan, Finland).
The lung tissue pathological examination
Lung tissue samples were fixed in 10% formalin and
embedded with paraffin,sections were cut at 5 μm thick-
ness and were stained with hematoxylin eosin (HE).
Statistical analysis
The data from test groups were evaluated by Student’st-
test. The survival rates of mice in test and control
groups were compared by using Fisher’se x a c tt e s t .A l l
differences were considered significant at P values0.05.
Results
Screening, ELISA and sequences of different antibody-
reactive phages
With H2N2 monoclonal antibody C179 as bait protein,
binding phages from Ph.D.-7, Ph.D.-12 and Ph.D.-C7C
peptide phage-display libraries were enriched by three
rounds of binding-elution-amplification. Thirty-two
binding phage clones were picked up randomly from
every library for ELISA testing with C179 coated and
uncoated wells (BSA blocked). Twelve phage clones with
higher ELISA signal ratio (C179 to BSA) were chosen for
single-strand DNA preparation and DNA sequencing. As
shown in Figure 1, the overall binding affinity of linear 7-
mer and cyclic 7-mer peptide-displayed phages to C179
was much lower than that of linear 12-mer group. The
clone H2-12-22 had the highest ELISA signal ratio in lin-
ear 12-mer group, which was above 10. In linear 7-mer
group, the clone H2-7-18 had the highest ELISA signal
ratio of 3.89. In cyclic 7-mer group, the clone H2-C7-29
had the highest ELISA signal ratio of 2.55 (Figure 1). The
selected phages were amplified in bacteria ER2738 and
their single-strand DNA was extracted for gene sequen-
cing. The peptide sequences were summarized in Table
1. The dominant sequences were considered as the
mimotopes of the influenza A virus A/Okuda/57 strain,
according to C179 monoclonal antibody. The linear hep-
topeptide WHWRLPS, linear dodecapeptide
WHTHKWSLSAKA and cyclic cysteine-restricted hepto-
peptide NLSSSWI had low similarity (Table 1).
Figure 1 The ELISA results of top 12 phage clones with higher C179/BSA ELISA signal ratio from Ph.D. -7, Ph.D. -12 and Ph.D. -C7C
peptide phage-display libraries. a: Phage clones from Ph.D. -7 peptide phage-display library. b: Phage clones from Ph.D. -12 peptide phage-
display library; c: Phage clones from Ph.D. -C7C peptide phage-display library.
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tide phages binding to IV.C102 H1N1 monoclonal anti-
body was QWTWTQY, whereas the linear
dodecapeptide was DCWQMDRKTCPL, cyclic hepto-
peptide was PLHARLP. All sequences and their frequen-
cies were listed in Table 2.
The dominant sequence displayed on linear heptopep-
tide phages binding to swine-origin influenza virus A
sera was ETKAWWL, whereas the linear dodecapeptide
was QAHNWYNHKPLP, cyclic heptopeptide was
PLHARLP. All sequences and their frequencies were
listed in Table 3.
The dominant sequence displayed on linear heptopep-
tide phages binding to influenza A virus A/H3N2 poly-
clonal IgG was WPWHNHR, whereas the linear
dodecapeptide was VWSTPPHADGPA, cyclic heptopep-
tide was LGALSHT. All sequences and their frequencies
were listed in Table 4.
Multi-mimotope gene synthesis
The multi-mimotope SIV7-SIV12-H1N17-H1N112-
H3N27-H3N212-H2N27- H2N212 of influenza A cov-
ered the mimotopes of H2N2, H1N1, H3N2 and SIV sub-
types. Each subtype contained heptopeptide and
dodecapeptide mimotopes. The whole amino acids
sequence and nucleotide sequence were shown in Table 5
Multi-mimotope expression and purification
T h em u l t i - m i m o t o p eg e n ew a ss u b c l o n e di n t op G E X - 2
T-1, pGEX-4 T-1 and pET43a (+) expression plasmids,
respectively. Their reading frames were confirmed by
EcoR I/BamH I digestion and gene sequencing. After
transforming into BL21 (DE3) E. coli cells and inducing
with IPTG, the multi-mimotope genes were expressed
as GST-fused protein with pGEX-2 T-1, pGEX-4 T-1
plasmids or as Nus/His6-fused protein with pET43a (+)
plasmid. The proteins were of 42KD and 73KD in
respective fused forms.
Large portion of Nus/His6-fusion multi-mimotope was
produced as soluble form; in contrast, the GST-fusion
proteins were expressed as insoluble form. So, BL21
(DE3) E. coli cells containing pET43a (+)-multi-mimo-
tope plasmids were chosen for induction with IPTG.
The Nus/His6-fusion multi-mimotope with endogenous
His6 tag was bound by Ni
2+-NTA-resin and eluted with
TBS containing 60 mM imidazole (Figure 2a). The imi-
dazole gradient was further investigated with the conse-
quence that fusion protein could be eluted completely
between 10 to 30 mM imidazole in TBS (Figure 2b).
The eluted protein was dialyzed against TBS containing
5m Mi m i d a z o l ea n dl o a d e do np r e - e q u i l i b r a t e dN i
2
+-NTA-resin for further affinity purification. This time,
the eluted protein was of high purity (Figure 2c).
Table 1 The phage-displayed peptides bound to C179 monoclonal antibody and their frequencies
Linear 7-mer Linear 12-mer Cyclic 7-mer
Peptide sequences Frequency Peptide sequences Frequency Peptide sequences Frequency
WHWRLPS 10/12 WHTHKWSLSAKA 4/12 NLSSSWI 9/12
LHHKTHH 2/12 HHWKFFFSHPGA 2/12 NSGMFVR 3/12
HHWKFFFSHPGE 2/12
LPFHGHKKPVLS 1/12
WPWWPGHTHRTI 1/12
HPMKQYRWRPSI 1/12
SPNYWFNKIHQH 1/12
Table 2 The phage-displayed peptides bound to IV.C102 monoclonal antibody and their frequencies
Linear 7-mer Linear 12-mer Cyclic 7-mer
Peptide sequences Frequency Peptide sequences Frequency Peptide sequences Frequency
QWTWTQY 4/12 DCWQMDRKTCPL 6/12 PLHARLP 10/12
DTLPLFI 1/12 NTPAWLNHTTVI 3/12 SLASLPA 2/12
MSLQQEH 1/12 LPAFFVTNQTQD 1/12
ANTTPRH 1/12 TVHWWZTHGPLS 1/12
MDAHHAL 1/12 SAIPTTWNPLAV 1/12
ITAPHPH 1/12
QRNQTQD 1/12
QWNRTQY 1/12
NTAPHPH 1/12
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The results (Figure 3) showed that the recombinant pro-
tein could be bound by H2N2 monoclonal antibody
(C179), H1N1 monoclonal antibody (IV.C102), goat
H3N2 polyclonal antibody and human SIV sera, respec-
tively. But the control protein BSA could not.
Prophylactic efficacy studies in mice
Fourteen days after A/Puerto Rico/8/1934 (H1N1) virus
challenge, 9 of the 9 mice in PBS group, 7 of the 9 mice
in 50 μg multi-mimotope i.p. group, 5 of the 9 mice in
100 μg multi-mimotope i.p. group and 8 of the 9 mice
in 100 μg multi-mimotope s.c. group died. However,
only 2 of the 9 mice in 200 μg multi-mimotope i.p.
group died (Figure 4a). Six days after virus challenge,
mice in PBS group lost 32% body weight, compared
with 19% in 50 μg multi-mimotope i.p. group, 16% in
100 μg multi-mimotope i.p. group, 8% in 200 μgm u l t i -
mimotope i.p. group and 23% in 100 μg multi-mimotope
s.c. group (Figure 4b). These findings suggested that
multi-mimotope effectively reduced infection of influ-
enza virus A.
Sera were collected and pooled from mice infected
with A/PR8 (H1N1) influenza virus. The ELISA method
was used to detect IgG Ab titers against H1N1 influenza
viruses. As shown in Figure 5, the immune responses to
PBS and unimmunized control mice were very low. For
the mice, immunization with 200 μgm u l t i - m i m o t o p e
induced antigen-specific Abs. The specific IgG Abs in
immunized mice after infected with H1N1 influenza
virus were significantly increased.
The lung tissue pathological changes
Gross lesions were observed in the lungs of mice of the
unimmunized infected groups,including pulmonary
hyperemia,hemorrhage and consolidation. Importantly,
the lung inflammation levels of the 200 μg multi-mimo-
tope immunized infected group were significantly
decreased compared with those of the matched unim-
munized infected groups. Necrotizing interstitial pneu-
monia was found with light microscope in all cases of
death in the unimmunized infected groups. The pul-
monary tissue exhibited hyperemia, emorrhage and
inflammatory exudation, leading to consolidation. The
lumina of alveoli and bronchioles were variably filled
with protein-rich edema fluid, fibrin, erythrocytes and
cell debris, admixed with many neutrophils and lympho-
cytes in the unimmunized infected groups (Figure 6).
Discussion
Current trivalent influenza vaccines can elicit produc-
tion of neutralization antibody to benefit human beings
[5,19-23]. However, the influenza vaccine must be
updated each year based on global influenza surveillance
due to rapid genetic shift and drift [9,10]. Developing a
new vaccine that induces neutralization antibodies
against multiple subtypes of influenza A is a promising
strategy for the disease control [24]. It has been
Table 3 The phage-displayed peptides bound to SIV sera and their frequencies
Linear 7-mer Linear 12-mer Cyclic 7-mer
Peptide sequences Frequency Peptide sequences Frequency Peptide sequences Frequency
ETKAWWL 7/12 QAHNWYNHKPLP 6/12 PLHARLP 6/12
LASKPMP 4/12 VHNNAARTGSPP 2/12 RHLPLTP 1/12
QAHTIST 1/12 VHNHANDPGSPP 1/12 SLPLTGQ 1/12
QELYPYSPHIHV 1/12 PSYPLSF 1/12
FSHELSWKPRKA 1/12 RDISPLA 1/12
AHTHSKERVQTI 1/12 YGWPIYS 1/12
NLSSSWT 1/12
Table 4 The phage-displayed peptides bound to H3N2 polyclonal antibody and their frequencies
Linear 7-mer Linear 12-mer Cyclic 7-mer
Peptide sequences Frequency Peptide sequences Frequency Peptide sequences Frequency
WPWHNHR 6/12 VWSTPPHADGPA 4/12 LGALSHT 8/12
ASINSSL 2/12 HAPWRHHQASPK 3/12 SPVLPFL 1/12
QSERAIQ 1/12 FPAHPAWTIGSM 1/12 THEPSGR 1/12
TSLPTIV 1/12 YTPLSSASPWGP 1/12 SAPRQAD 1/12
AFSYHIH 1/12 GMSLLHGQRPHT 1/12 SLPLTGQ 1/12
NMWQALN 1/12 VSRHQSWHPHDL 1/12
EREAHQLHSHHK 1/12
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tive antibodies, and consequently, become candidates for
the development of potential vaccines [25-28]. The
phage-displayed mimotopes from random peptide
libraries have recently been shown to be possible vac-
cine components that do not necessarily represent the
structural equivalents of the original antigen, but pro-
vide functional images that could replace the original
epitopes for vaccine development [29].
In the case of mimotope immunisation, several studies
have shown effective responses in vivo [30,31]. Further-
more, protective immune responses by mimotope
immunisation have been verified in many infectious dis-
eases [11-14].
Monoclonal antibody C179, antigen binding fragment
(Fab) CR6261 and single-chain variable fragment anti-
body (scFv) F10 recognize conserved epitope of hemag-
glutinin across different subtypes of influenza A viruses
Table 5 The amino acids sequence and nucleotide sequence of multi-mimotope of influenza A
ETKAWWLGSGGSQAHNWYNHKPLPGSG
gaaactaaagcatggtggctgggttctggtggttctcaggctcataactggtataaccataagccactgccaggttccggt
GSQWTWTQYGSGGSDCWQMDRKTCPLG
ggttctcagtggacttggacgcagtacggtagcggtggctccgactgttggcagatggatcgcaaaacctgtccactgggt
SGGSWPWHNHRGSGGSVWSTPPHADGP
tctggcggtagctggccttggcataaccatcgtggcagcggtggttctgtttggtctactccaccgcatgctgatggtcca
AGSGGSWHWRLPSGSGGSWHTHKWSLS
gctggctctggcggttcttggcattggcgtctgccatctggctctggtggttcttggcacactcacaaatggtctctgtct
AKA
gctaaagca
Figure 2 The purification of recombinant multi-mimotope of influenza A virus. a: The multi-mimotope was expressed in soluble form in
bacteria and purified with affinity chromatography (lane 1: protein marker: 116.0, 66.2, 45.0, 35.0, 25.0, 18.4, 14.4KDa; lane 2: multi-mimotope
gene was transferred to bacteria and induced with IPTG; lane 3: supernatant of ultrasound-broken bacteria; lane 4: pellete of ultrasound-broken
bacteria; lane 5: flow-through of supernatant loaded on Ni
2+-NTA-resin; lane 6: first 0.25 ml elution from 0.25 ml Ni
2+-NTA-resin with 60 mM
imidazole; lane 7: second 0.25 ml elution from Ni
2+-NTA-resin with 60 mM imidazole; lane 8-9: elution from Ni
2+-NTA-resin with 1 M imidazole).
b: The optimized concentration gradient between 5 and 60 mM imidazole for affinity chromatography (lane 1: protein marker: 97.4, 66.4,
43.0KDa; lane 2-3: elution from Ni
2+-NTA-resin with 5 mM imidazole; lane 4-5: elution from Ni
2+-NTA-resin with 10 mM imidazole; lane 6-7:
elution from Ni
2+-NTA-resin with 30 mM imidazole; lane 8-9: elution from Ni
2+-NTA-resin with 60 mM imidazole). c: The multi-mimotope was
purified with repeat affinity chromatography (lane 1: protein marker: 116.0, 66.2, 45.0, 35.0, 25.0, 18.4, 14.4KDa; lane 2: supernatant of ultrasound-
broken bacteria; lane 3: multi-mimotope purified by repeat affinity chromatography).
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Figure 4 The prophylactic effect of multi-mimotope agaist influenza virus challenge. a: The survival rate of mice after virus challenge
following multi-mimotope vaccination. b: The body weight loss of mice after virus challenge following multi-mimotope vaccination.
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Page 8 of 11[1,3,15]. To mimic the conformational structure of the
conserved motif, the peptide phage display technique
was used in this paper to screen the mimotope with
commercial C179 monoclonal antibody. Although C179
was produced by immunization of influenza A virus A/
Okuda/57 strain (H2N2 subtype) can block membrane
fusion rather than cell attachment and protect mice
against viral challenge [32]. And its binding activities
Figure 5 Serum IgG Ab titers were detected by ELISA. Nine mice were immunised with 200 μg multi-mimotope. The mice were bled once
(unimmunized serum), and were bled every 10 days after the booster immunization (immunized serum). Ten days after the booster injection,
mice were challenged with H1N1 virus by intranasal inoculation of 50 μl per mouse. Two weeks after challenge, mice were sacrificed for the
anti-H1N1 IgG Ab detection by ELISA (immunized infected serum). Triplicate ELISAs were performed to test each serum sample. All assays were
carried out in triplicate and the error bars indicate standard deviation.
Figure 6 The lung tissue pathological changes. A: the unimmunized infected group (×200). The lung tissue pathological changes from the
unimmunized infected groups died on day 6. Necrotizing interstitial pneumonia was found in all cases of death. The pulmonary tissue exhibited
hyperemia,hemorrhage,and inflammatory exudation. B: the 200 μg multi-mimotope immunized infected group (×200). The lung tissue
pathological changes from the 200 μg multi-mimotopes immunized infected group on day 14. Showing the lung inflammation level were
significantly decreased compared with those of their matched unimmunized infected group.
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Page 9 of 11can be detected in H1 influenza A viruses, and possibly
in H4 to H6, H8, H9, H11 to H14 and H16 influenza A
viruses. In addition, H3N2 and H1N1 antibodies, espe-
cially swine-origin influenza sera were used to screen
different types of mimotopes. The Ph.D.-7, Ph.D.-12 and
Ph.D.-C7C peptide phage-display libraries with different
lengths and formats of peptides were utilized to screen
mimotopes. The individual mimotope was linked by
GSGGS with the sequence SIV7-SIV12-H1N17-
H1N112-H3N27-H3N212-H2N27-H2N212, which was
used to test whether the synthetic gene with multiple
GSGGS inserting affected the expression. The synthetic
gene with multiple GSGGS was expressed successfully
in E. coli, which was confirmed by SDS-PAGE [33].
In recent years, the universal influenza vaccines have
been under investigation worldwide, including conserved
epitope of surface M2 [34-36]. However all developed
vaccines were far from the clinical needs [37]. In this
paper, we utilized C179 to screen the mimotopes to
hemagglutinin of influenza virus. The recombinant
multi-mimotope covered the other mimotopes of
hemagglutinin to increase its efficacy and versatility.
The multi-mimotopes effectively protected animals from
influenza A virus challenge. The recombinant multi-
mimotopes could provide a novel and promising vaccine
candidate for inducing a broad immune response.
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